{"id":2451,"date":"2010-06-07T03:00:00","date_gmt":"2010-06-07T03:00:00","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/hbped\/"},"modified":"2025-05-14T19:08:51","modified_gmt":"2025-05-14T19:08:51","slug":"hbped","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/hbped\/","title":{"rendered":"Fototerapia y Transfusi\u00f3n de Intercambio en Hiperbilirrubinemia Neonatal"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p><span class=\"long_text\">En la hiperbilirrubinemia no conjugada, el objetivo final es la prevenci\u00f3n de kernicterus y sus efectos potencialmente devastadores.<br \/>\nLa fototerapia ha representado un<\/span><span class=\"long_text\">\u00a0importante<\/span><span class=\"long_text\">\u00a0avance en el tratamiento de la ictericia, logrando una efectiva y relativamente\u00a0<\/span><span class=\"long_text\">r\u00e1pida reducci\u00f3n\u00a0<\/span><span class=\"long_text\">de los elevados niveles de bilirrubina y facilitando la prevenci\u00f3n del kernicterus.<br \/>\nLa exanguinotransfusi\u00f3n es la \u00fanica alternativa a la fototerapia para el control de la hiperbilirrubinemia.<\/span><br \/>\n<!--more--><br \/>\n<strong>R<span class=\"medium_text\">ecomendaciones para fototerapia de la\u00a0<\/span>American Academy of Pediatrics<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr>\n<td rowspan=\"3\">\u00a0Categor\u00eda de riesgo<\/td>\n<td colspan=\"5\" align=\"center\">\u00a0Bilirubina s\u00e9rica total (mg\/dL)<\/td>\n<\/tr>\n<tr align=\"center\">\n<td colspan=\"5\">\u00a0Edad (h)<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">\u00a024<\/td>\n<td align=\"center\">\u00a036<\/td>\n<td align=\"center\">\u00a048<\/td>\n<td align=\"center\">\u00a072<\/td>\n<td align=\"center\">\u00a096<\/td>\n<\/tr>\n<tr>\n<td>Riesgo elevado (35\u201337 semanas + factores de riesgo<sup>a<\/sup>)<\/td>\n<td align=\"center\">\u00a08<\/td>\n<td align=\"center\">\u00a09<\/td>\n<td align=\"center\">\u00a011<\/td>\n<td align=\"center\">\u00a013<\/td>\n<td align=\"center\">\u00a014<\/td>\n<\/tr>\n<tr>\n<td>Riesgo intermedio (&gt;\/=38 semanas + factores de riesgo o 35\u201337 semanas y en buen estado general)<\/td>\n<td align=\"center\">\u00a010<\/td>\n<td align=\"center\">\u00a012<\/td>\n<td align=\"center\">\u00a013<\/td>\n<td align=\"center\">\u00a015<\/td>\n<td align=\"center\">\u00a017<\/td>\n<\/tr>\n<tr>\n<td>Riesgo bajo (&gt;38 semanas y en buen estado general)<\/td>\n<td align=\"center\">\u00a012<\/td>\n<td align=\"center\">\u00a013<\/td>\n<td align=\"center\">\u00a015<\/td>\n<td align=\"center\">\u00a018<\/td>\n<td align=\"center\">\u00a020<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><sup>a<\/sup><span class=\"medium_text\">Los factores de riesgo se definen como una enfermedad hemol\u00edtica isoinmune, deficiencia de G6PD, asfixia, letargo significativo, inestabilidad t\u00e9rmica, sepsis, acidosis.<\/span><\/p>\n<p><strong>Recomendaciones para transfusi\u00f3n de intercambio de la American Academy of Pediatrics<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr>\n<td rowspan=\"3\">\u00a0Categor\u00eda de riesgo<\/td>\n<td colspan=\"5\" align=\"center\">\u00a0Bilirubina s\u00e9rica total (mg\/dL)<\/td>\n<\/tr>\n<tr align=\"center\">\n<td colspan=\"5\">\u00a0Edad (h)<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">\u00a024<\/td>\n<td align=\"center\">\u00a036<\/td>\n<td align=\"center\">\u00a048<\/td>\n<td align=\"center\">\u00a072<\/td>\n<td align=\"center\">\u00a096<\/td>\n<\/tr>\n<tr>\n<td>Riesgo elevado (35\u201337 semanas + factores de riesgo<sup>a<\/sup>)<\/td>\n<td align=\"center\">\u00a015<\/td>\n<td align=\"center\">\u00a016<\/td>\n<td align=\"center\">\u00a017<\/td>\n<td align=\"center\">\u00a018<\/td>\n<td align=\"center\">\u00a019<\/td>\n<\/tr>\n<tr>\n<td>Riesgo intermedio (&gt;\/=38 semanas + factores de riesgo o 35\u201337 semanas y en buen estado general)<\/td>\n<td align=\"center\">\u00a016.5<\/td>\n<td align=\"center\">\u00a018<\/td>\n<td align=\"center\">\u00a019<\/td>\n<td align=\"center\">\u00a020<\/td>\n<td align=\"center\">\u00a022<\/td>\n<\/tr>\n<tr>\n<td>Riesgo bajo (&gt;38 semanas y en buen estado general)<\/td>\n<td align=\"center\">\u00a019<\/td>\n<td align=\"center\">\u00a021<\/td>\n<td align=\"center\">\u00a022<\/td>\n<td align=\"center\">\u00a024<\/td>\n<td align=\"center\">\u00a025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><sup>a<\/sup><span class=\"medium_text\">Los factores de riesgo se definen como una enfermedad hemol\u00edtica isoinmune, deficiencia de G6PD, asfixia, letargo significativo, inestabilidad t\u00e9rmica, sepsis, acidosis.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Bibliograf\u00eda:<\/strong><\/p>\n<ol>\n<li>Rennie JM, Sehgal A, De A, Kendall GS, Cole TJ. Range of UK practice regarding thresholds for phototherapy and exchange transfusion in neonatal hyperbilirubinaemia. Arch Dis Child Fetal Neonatal Ed. 2009 Sep;94(5):F323-7.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19000996\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Colletti JE, Kothari S, Jackson DM, Kilgore KP, Barringer K. An emergency medicine approach to neonatal hyperbilirubinemia. Emerg Med Clin North Am. 2007 Nov;25(4):1117-35\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17950138\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul;114(1):297-316.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15231951\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Creado: May 26, 2010<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>En la hiperbilirrubinemia no conjugada, el objetivo final es la prevenci\u00f3n de kernicterus y sus efectos potencialmente devastadores. La fototerapia ha representado un\u00a0importante\u00a0avance en el tratamiento de la ictericia, logrando una efectiva y relativamente\u00a0r\u00e1pida reducci\u00f3n\u00a0de los elevados niveles de bilirrubina y facilitando la prevenci\u00f3n del kernicterus. La exanguinotransfusi\u00f3n es la \u00fanica alternativa a la fototerapia [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[441],"tags":[1309,1310,1311,1312,447,667,1313],"class_list":["post-2451","post","type-post","status-publish","format-standard","hentry","category-pediatrics","tag-exchange-transfusion","tag-hiperbilirrubinemia","tag-hyperbilirubinaemia","tag-luminoterapia","tag-neonatal","tag-pediatrics","tag-phototherapy"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=2451"}],"version-history":[{"count":3,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2451\/revisions"}],"predecessor-version":[{"id":9352,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2451\/revisions\/9352"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=2451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=2451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=2451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}